Table of Contents Author Guidelines Submit a Manuscript
Experimental Diabetes Research
Volume 2012, Article ID 470851, 12 pages
http://dx.doi.org/10.1155/2012/470851
Review Article

Physiology and Emerging Biochemistry of the Glucagon-Like Peptide-1 Receptor

1Translational Science and Technologies, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
2Endocrine Discovery, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA

Received 31 December 2011; Accepted 25 January 2012

Academic Editor: Matteo Monami

Copyright © 2012 Francis S. Willard and Kyle W. Sloop. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. A. Nauck, E. Homberger, and E. G. Siegel, “Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses,” The Journal of Clinical Endocrinology & Metabolism, vol. 63, no. 2, pp. 492–498, 1986. View at Google Scholar · View at Scopus
  2. H. Elrick, L. Stimmler, C. J. Hlad, and Y. ARAI, “Plasma insulin response to oral and intravenous glucose administration,” The Journal of Clinical Endocrinology & Metabolism, vol. 24, pp. 1076–1082, 1964. View at Google Scholar · View at Scopus
  3. M. J. Perley and D. M. Kipnis, “Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects,” Journal of Clinical Investigation, vol. 46, no. 12, pp. 1954–1962, 1967. View at Google Scholar · View at Scopus
  4. N. Mcintyre, C. D. Holdsworth, and D. S. Turner, “New interpretation of oral glucose tolerance,” The Lancet, vol. 2, no. 7349, pp. 20–21, 1964. View at Google Scholar · View at Scopus
  5. R. H. Unger and A. M. Eisentraut, “Entero-insular axis,” Archives of Internal Medicine, vol. 123, no. 3, pp. 261–266, 1969. View at Google Scholar · View at Scopus
  6. C. Orskov, J. J. Holst, and O. V. Nielsen, “Effect of truncated glucagon-like peptide-1 [Proglucagon-(78–107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach,” Endocrinology, vol. 123, no. 4, pp. 2009–2013, 1988. View at Google Scholar · View at Scopus
  7. J. J. Holst, C. Orskov, O. V. Nielsen, and T. W. Schwartz, “Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut,” FEBS Letters, vol. 211, no. 2, pp. 169–174, 1987. View at Google Scholar · View at Scopus
  8. B. Kreymann, G. Williams, M. A. Ghatei, and S. R. Bloom, “Glucagon-like peptide-1 7–36: a physiological incretin in man,” The Lancet, vol. 2, no. 8571, pp. 1300–1304, 1987. View at Google Scholar · View at Scopus
  9. R. M. Elliott, L. M. Morgan, J. A. Tredger, S. Deacon, J. Wright, and V. Marks, “Glucagon-like peptide-1(7–36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24−h secretion patterns,” Journal of Endocrinology, vol. 138, no. 1, pp. 159–166, 1993. View at Google Scholar · View at Scopus
  10. K. B. Lauritsen, A. J. Moody, K. C. Christensen, and S. Lindkaer Jensen, “Gastric inhibitory polypeptide (GIP) and insulin release after small-bowel resection in man,” Scandinavian Journal of Gastroenterology, vol. 15, no. 7, pp. 833–840, 1980. View at Google Scholar · View at Scopus
  11. S. Mojsov, G. C. Weir, and J. F. Habener, “Insulinotropin: glucagon-like peptide I (7–37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas,” Journal of Clinical Investigation, vol. 79, no. 2, pp. 616–619, 1987. View at Google Scholar · View at Scopus
  12. J. C. Brown, “Gastric inhibitory polypeptide,” Monographs on Endocrinology, vol. 24, pp. 1–88, 1982. View at Google Scholar · View at Scopus
  13. J. Dupre, S. A. Ross, D. Watson, and J. C. Brown, “Stimulation of insulin secretion by gastric inhibitory polypeptide in man,” The Journal of Clinical Endocrinology & Metabolism, vol. 37, no. 5, pp. 826–828, 1973. View at Google Scholar · View at Scopus
  14. J. M. Falko, S. E. Crockett, S. Cataland, and E. L. Mazzaferri, “Gastric inhibitory polypeptide (GIP) stimulated by fat ingestion in man,” The Journal of Clinical Endocrinology & Metabolism, vol. 41, no. 2, pp. 260–265, 1975. View at Google Scholar · View at Scopus
  15. F. B. Thomas, E. L. Mazzaferri, and S. E. Crockett, “Stimulation of secretion of gastric inhibitory polypeptide and insulin by intraduodenal amino acid perfusion,” Gastroenterology, vol. 70, no. 4, pp. 523–527, 1976. View at Google Scholar · View at Scopus
  16. T. Kauth and J. Metz, “Immunohistochemical localization of glucagon-like peptide 1. Use of poly- and monoclonal antibodies,” Histochemistry, vol. 86, no. 5, pp. 509–515, 1987. View at Google Scholar · View at Scopus
  17. R. Eissele, R. Goke, S. Willemer et al., “Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man,” European Journal of Clinical Investigation, vol. 22, no. 4, pp. 283–291, 1992. View at Google Scholar · View at Scopus
  18. G. I. Bell, R. Sanchez Pescador, P. J. Laybourn, and R. C. Najarian, “Exon duplication and divergence in the human preproglucagon gene,” Nature, vol. 304, no. 5924, pp. 368–371, 1983. View at Google Scholar · View at Scopus
  19. J. J. Holst, “Gut glucagon, enteroglucagon, gut glucagonlike immunoreactivity, glicentin—current status,” Gastroenterology, vol. 84, no. 6, pp. 1602–1613, 1983. View at Google Scholar · View at Scopus
  20. Y. Rouille, S. Kantengwa, J. C. Irminger, and P. A. Halban, “Role of the prohormone convertase PC3 in the processing of proglucagon to glucagon-like peptide 1,” The Journal of Biological Chemistry, vol. 272, no. 52, pp. 32810–32816, 1997. View at Publisher · View at Google Scholar · View at Scopus
  21. X. Zhu, A. Zhou, A. Dey et al., “Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 16, pp. 10293–10298, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. M. E. Rothenberg, C. D. Eilertson, K. Klein et al., “Processing of mouse proglucagon by recombinant prohormone convertase 1 and immunopurified prohormone convertase 2 in vitro,” The Journal of Biological Chemistry, vol. 270, no. 17, pp. 10136–10146, 1995. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Takeda, Y. Seino, K. Tanaka et al., “Sequence of an intestinal cDNA encoding human gastric inhibitory polypeptide precursor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 20, pp. 7005–7008, 1987. View at Google Scholar · View at Scopus
  24. A. M. Buchan, J. M. Polak, and C. Capella, “Electronimmunocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) in man,” Histochemistry, vol. 56, no. 1, pp. 37–44, 1978. View at Google Scholar · View at Scopus
  25. B. Thorens, “Expression cloning of the pancreatic beta cell receptor for the gluco- incretin hormone glucagon-like peptide 1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 18, pp. 8641–8645, 1992. View at Google Scholar · View at Scopus
  26. B. Thorens, A. Porret, L. Buhler, S. P. Deng, P. Morel, and C. Widmann, “Cloning and functional expression of the human islet GLP-1 receptor: demonstration that exendin-4 is an agonist and exendin-(9–39) an antagonist of the receptor,” Diabetes, vol. 42, no. 11, pp. 1678–1682, 1993. View at Google Scholar · View at Scopus
  27. T. B. Usdin, E. Mezey, D. C. Button, M. J. Brownstein, and T. I. Bonner, “Gastric inhibitory polypeptide receptor, a member of the secretin- vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain,” Endocrinology, vol. 133, no. 6, pp. 2861–2870, 1993. View at Publisher · View at Google Scholar · View at Scopus
  28. F. Preitner, M. Ibberson, I. Franklin et al., “Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors,” Journal of Clinical Investigation, vol. 113, no. 4, pp. 635–645, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Jorgensen, L. Martini, T. W. Schwartz, and C. E. Elling, “Characterization of glucagon-like peptide-1 receptor beta-arrestin 2 interaction: a high-affinity receptor phenotype,” Molecular Endocrinology, vol. 19, no. 3, pp. 812–823, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. N. Sonoda, T. Imamura, T. Yoshizaki, J. L. Babendure, J. C. Lu, and J. M. Olefsky, “Beta-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic beta cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 18, pp. 6614–6619, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. I. Dzhura, O. G. Chepurny, G. G. Kelley et al., “Epac2-dependent mobilization of intracellular Ca2+ by glucagon-like peptide-1 receptor agonist exendin-4 is disrupted in beta-cells of phospholipase C-beta knockout mice,” Journal of Physiology, vol. 588, part 24, pp. 4871–4889, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. M. S. Islam, “Calcium signaling in the islets,” Advances in Experimental Medicine and Biology, vol. 654, pp. 235–259, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Nauck, F. Stockmann, R. Ebert, and W. Creutzfeldt, “Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes,” Diabetologia, vol. 29, no. 1, pp. 46–52, 1986. View at Google Scholar · View at Scopus
  34. I. R. Jones, D. R. Owens, A. J. Moody, S. D. Luzio, T. Morris, and T. M. Hayes, “The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and Type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion,” Diabetologia, vol. 30, no. 9, pp. 707–712, 1987. View at Google Scholar · View at Scopus
  35. T. Krarup, N. Saurbrey, and A. J. Moody, “Effect of porcine gastric inhibitory polypeptide on beta-cell function in type I and type II diabetes mellitus,” Metabolism, vol. 36, no. 7, pp. 677–682, 1987. View at Google Scholar · View at Scopus
  36. M. A. Heimesaat, C. Orskov, J. J. Holst, R. Ebert, and W. Creutzfeldt, “Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus,” Journal of Clinical Investigation, vol. 91, no. 1, pp. 301–307, 1993. View at Google Scholar · View at Scopus
  37. D. M. Nathan, E. Schreiber, H. Fogel, S. Mojsov, and J. F. Habener, “Insulinotropic action of glucagonlike peptide-I-(7–37) in diabetic and nondiabetic subjects,” Diabetes Care, vol. 15, no. 2, pp. 270–276, 1992. View at Google Scholar · View at Scopus
  38. M. Gutniak, C. Orskov, J. J. Holst, B. Ahren, and S. Efendic, “Antidiabetogenic effect of glucagon-like peptide-1 (7–36)amide in normal subjects and patients with diabetes mellitus,” The New England Journal of Medicine, vol. 326, no. 20, pp. 1316–1322, 1992. View at Google Scholar · View at Scopus
  39. M. A. Nauck, N. Kleine, C. Orskov, J. J. Holst, B. Willms, and W. Creutzfeldt, “Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in Type 2 (non-insulin-dependent) diabetic patients,” Diabetologia, vol. 36, no. 8, pp. 741–744, 1993. View at Google Scholar · View at Scopus
  40. M. A. Nauck et al., “Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans,” American Journal of Physiology, vol. 273, no. 5, part 1, pp. E981–E988, 1997. View at Google Scholar · View at Scopus
  41. B. Willms, J. Werner, J. J. Holst, C. Ørskov, W. Creutzfeldt, and M. A. Nauck, “Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7–36) amide in type 2 (noninsulin-dependent) diabetic patients,” The Journal of Clinical Endocrinology & Metabolism, vol. 81, no. 1, pp. 327–332, 1996. View at Google Scholar · View at Scopus
  42. J. M. Wishart, M. Horowitz, H. A. Morris, K. L. Jones, and M. A. Nauck, “Relation between gastric emptying of glucose and plasma concentrations of glucagon-like peptide-1,” Peptides, vol. 19, no. 6, pp. 1049–1053, 1998. View at Publisher · View at Google Scholar · View at Scopus
  43. K. Meeran, D. O'Shea, C. M. B. Edwards et al., “Repeated intracerebroventricular administration of glucagon-like peptide-1-(7–36) amide or exendin-(9–39) alters body weight in the rat,” Endocrinology, vol. 140, no. 1, pp. 244–250, 1999. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Flint, A. Raben, A. Astrup, and J. J. Holst, “Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans,” Journal of Clinical Investigation, vol. 101, no. 3, pp. 515–520, 1998. View at Google Scholar · View at Scopus
  45. J. P. Gutzwiller, J. Drewe, B. Göke et al., “Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2,” American Journal of Physiology, vol. 276, no. 5, part 2, pp. R1541–R1544, 1999. View at Google Scholar · View at Scopus
  46. J. P. Gutzwiller, B. Göke, J. Drewe et al., “Glucagon-like peptide-1: a potent regulator of food intake in humans,” Gut, vol. 44, no. 1, pp. 81–86, 1999. View at Google Scholar · View at Scopus
  47. M. D. Turton, D. O'Shea, I. Gunn et al., “A role for glucagon-like peptide-1 in the central regulation of feeding,” Nature, vol. 379, no. 6560, pp. 69–72, 1996. View at Publisher · View at Google Scholar · View at Scopus
  48. R. Mentlein, B. Gallwitz, and W. E. Schmidt, “Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum,” European Journal of Biochemistry, vol. 214, no. 3, pp. 829–835, 1993. View at Google Scholar · View at Scopus
  49. C. F. Deacon, A. H. Johnsen, and J. J. Holst, “Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo,” The Journal of Clinical Endocrinology & Metabolism, vol. 80, no. 3, pp. 952–957, 1995. View at Google Scholar · View at Scopus
  50. L. B. Knudsen and L. Pridal, “Glucagon-like peptide-1-(9–36) amide is a major metabolite of glucagon-like peptide-1-(7–36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor,” European Journal of Pharmacology, vol. 318, no. 2-3, pp. 429–435, 1996. View at Publisher · View at Google Scholar · View at Scopus
  51. L. Hansen, C. F. Deacon, C. Ørskov, and J. J. Holst, “Glucagon-like peptide-1-(7–36)amide is transformed to glucagon-like peptide-1-(9–36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine,” Endocrinology, vol. 140, no. 11, pp. 5356–5363, 1999. View at Google Scholar · View at Scopus
  52. C. F. Deacon, L. Pridal, L. Klarskov, M. Olesen, and J. J. Holst, “Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig,” American Journal of Physiology, vol. 271, no. 3, part 1, pp. E458–E464, 1996. View at Google Scholar · View at Scopus
  53. T. Vilsboll, H. Agersø, T. Krarup, and J. J. Holst, “Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects,” The Journal of Clinical Endocrinology & Metabolism, vol. 88, no. 1, pp. 220–224, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. E. G. Siegel, B. Gallwitz, G. Scharf et al., “Biological activity of GLP-1-analogues with N-terminal modifications,” Regulatory Peptides, vol. 79, no. 2-3, pp. 93–102, 1999. View at Publisher · View at Google Scholar
  55. U. Ritzel, U. Leonhardt, M. Ottleben et al., “A synthetic glucagon-like peptide-1 analog with improved plasma stability,” Journal of Endocrinology, vol. 159, no. 1, pp. 93–102, 1998. View at Publisher · View at Google Scholar · View at Scopus
  56. C. F. Deacon, L. B. Knudsen, K. Madsen, F. C. Wiberg, O. Jacobsen, and J. J. Holst, “Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity,” Diabetologia, vol. 41, no. 3, pp. 271–278, 1998. View at Publisher · View at Google Scholar · View at Scopus
  57. R. Goke, H. C. Fehmann, T. Linn et al., “Exendin-4 is a high potency agonist and truncated exendin-(9–39)-amide an antagonist at the glucagon-like peptide 1-(7–36)-amide receptor of insulin- secreting beta-cells,” The Journal of Biological Chemistry, vol. 268, no. 26, pp. 19650–19655, 1993. View at Google Scholar · View at Scopus
  58. H. C. Fehmann, J. Jiang, J. Schweinfurth, M. B. Wheeler, A. E. Boyd, and B. Goke, “Stable expression of the rat GLP-I receptor in CHO cells: activation and binding characteristics utilizing GLP-I(7–36)-amide, oxyntomodulin, exendin- 4, and exendin(9–39),” Peptides, vol. 15, no. 3, pp. 453–456, 1994. View at Publisher · View at Google Scholar · View at Scopus
  59. H. C. Fehmann, J. Jiang, J. Schweinfurth et al., “Ligand-specificity of the rat GLP-I receptor recombinantly expressed in Chinese hamster ovary (CHO-) cells,” Zeitschrift fur Gastroenterologie, vol. 32, no. 4, pp. 203–207, 1994. View at Google Scholar · View at Scopus
  60. J. Eng, W. A. Kleinman, L. Singh, G. Singh, and J. P. Raufman, “Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas,” The Journal of Biological Chemistry, vol. 267, no. 11, pp. 7402–7405, 1992. View at Google Scholar · View at Scopus
  61. J. Eng, P. C. Andrews, W. A. Kleinman, L. Singh, and J. P. Raufman, “Purification and structure of exendin-3, a new pancreatic secretagogue isolated from Heloderma horridum venom,” The Journal of Biological Chemistry, vol. 265, no. 33, pp. 20259–20262, 1990. View at Google Scholar · View at Scopus
  62. F. E. Russell and C. M. Bogert, “Gila monster: its biology, venom and bite—a review,” Toxicon, vol. 19, no. 3, pp. 341–359, 1981. View at Google Scholar · View at Scopus
  63. A. Thum, K. Hupe-Sodmann, R. Göke, K. Voigt, B. Göke, and G. P. McGregor, “Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4,” Experimental and Clinical Endocrinology and Diabetes, vol. 110, no. 3, pp. 113–118, 2002. View at Publisher · View at Google Scholar · View at Scopus
  64. C. M. Edwards, S. A. Stanley, R. Davis et al., “Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers,” American Journal of Physiology, vol. 281, no. 1, pp. E155–E161, 2001. View at Google Scholar
  65. L. Simonsen, J. J. Holst, and C. F. Deacon, “Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs,” Diabetologia, vol. 49, no. 4, pp. 706–712, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. N. H. Greig, H. W. Holloway, K. A. De Ore et al., “Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations,” Diabetologia, vol. 42, no. 1, pp. 45–50, 1999. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Szayna, M. E. Doyle, J. A. Betkey et al., “Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats,” Endocrinology, vol. 141, no. 6, pp. 1936–1941, 2000. View at Publisher · View at Google Scholar · View at Scopus
  68. A. A. Young, B. R. Gedulin, S. Bhavsar et al., “Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta),” Diabetes, vol. 48, no. 5, pp. 1026–1034, 1999. View at Publisher · View at Google Scholar · View at Scopus
  69. O. G. Kolterman, D. D. Kim, L. Shen et al., “Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus,” American Journal of Health-System Pharmacy, vol. 62, no. 2, pp. 173–181, 2005. View at Google Scholar · View at Scopus
  70. L. B. Knudsen, P. F. Nielsen, P. O. Huusfeldt et al., “Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration,” Journal of Medicinal Chemistry, vol. 43, no. 9, pp. 1664–1669, 2000. View at Publisher · View at Google Scholar · View at Scopus
  71. H. Agerso, L. B. Jensen, B. Elbrønd, P. Rolan, and M. Zdravkovic, “The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men,” Diabetologia, vol. 45, no. 2, pp. 195–202, 2002. View at Publisher · View at Google Scholar · View at Scopus
  72. B. Elbrond, G. Jakobsen, S. Larsen et al., “Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects,” Diabetes Care, vol. 25, no. 8, pp. 1398–1404, 2002. View at Publisher · View at Google Scholar · View at Scopus
  73. J. W. Neidigh, R. M. Fesinmeyer, K. S. Prickett, and N. H. Andersen, “Exendin-4 and glucagon-like-peptide-1: NMR structural comparisons in the solution and micelle-associated states,” Biochemistry, vol. 40, no. 44, pp. 13188–13200, 2001. View at Publisher · View at Google Scholar · View at Scopus
  74. C. R. Underwood, P. Garibay, L. B. Knudsen et al., “Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor,” The Journal of Biological Chemistry, vol. 285, no. 1, pp. 723–730, 2010. View at Publisher · View at Google Scholar · View at Scopus
  75. S. Runge, H. Thøgersen, K. Madsen, J. Lau, and R. Rudolph, “Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain,” The Journal of Biological Chemistry, vol. 283, no. 17, pp. 11340–11347, 2008. View at Publisher · View at Google Scholar · View at Scopus
  76. M. Castro, V. O. Nikolaev, D. Palm, M. J. Lohse, and J. P. Vilardaga, “Turn-on switch in parathyroid hormone receptor by a two-step parathyroid hormone binding mechanism,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 44, pp. 16084–16089, 2005. View at Publisher · View at Google Scholar · View at Scopus
  77. S. Al-Sabah and D. Donnelly, “A model for receptor-peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors,” British Journal of Pharmacology, vol. 140, no. 2, pp. 339–346, 2003. View at Publisher · View at Google Scholar · View at Scopus
  78. S. Runge, B. S. Wulff, K. Madsen, H. Bräuner-Osborne, and L. B. Knudsen, “Different domains of the glucagon and glucagon-like peptide-1 receptors provide the critical determinants of ligand selectivity,” British Journal of Pharmacology, vol. 138, no. 5, pp. 787–794, 2003. View at Publisher · View at Google Scholar · View at Scopus
  79. M. H. Perrin, C. R. R. Grace, R. Riek, and W. W. Vale, “The three-dimensional structure of the n-terminal domain of corticotropin-releasing factor receptors sushi domains and the B1 family of G protein-coupled receptors,” Annals of the New York Academy of Sciences, vol. 1070, pp. 105–119, 2006. View at Publisher · View at Google Scholar · View at Scopus
  80. A. A. Pioszak and H. E. Xu, “Molecular recognition of parathyroid hormone by its G protein-coupled receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 13, pp. 5034–5039, 2008. View at Publisher · View at Google Scholar · View at Scopus
  81. A. Bazarsuren, U. Grauschopf, M. Wozny et al., “In vitro folding, functional characterization, and disulfide pattern of the extracellular domain of human GLP-1 receptor,” Biophysical Chemistry, vol. 96, no. 2-3, pp. 305–318, 2002. View at Publisher · View at Google Scholar · View at Scopus
  82. S. R. Hoare, “Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors,” Drug Discovery Today, vol. 10, no. 6, pp. 417–427, 2005. View at Publisher · View at Google Scholar · View at Scopus
  83. L. Jin, S. L. Briggs, S. Chandrasekhar et al., “Crystal structure of human parathyroid hormone 1-34 at 0.9−A resolution,” The Journal of Biological Chemistry, vol. 275, no. 35, pp. 27238–27244, 2000. View at Publisher · View at Google Scholar · View at Scopus
  84. K. Thornton and D. G. Gorenstein, “Structure of glucagon-like peptide(7–36) amide in a dodecylphosphocholine micelle as determined by 2D NMR,” Biochemistry, vol. 33, no. 12, pp. 3532–3539, 1994. View at Google Scholar · View at Scopus
  85. N. H. Andersen, Y. Brodsky, J. W. Neidigh, and K. S. Prickett, “Medium-dependence of the secondary structure of exendin-4 and glucagon-like-peptide-1,” Bioorganic and Medicinal Chemistry, vol. 10, no. 1, pp. 79–85, 2002. View at Publisher · View at Google Scholar · View at Scopus
  86. C. A. Leech, O. G. Chepurny, and G. G. Holz, “Epac2-Dependent Rap1 Activation and the Control of Islet Insulin Secretion by Glucagon-Like Peptide-1,” Vitamins and Hormones, vol. 84, no. C, pp. 279–302, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. M. B. Wheeler, M. Lu, J. S. Dillon, X. H. Leng, C. Chen, and A. E. Boyd, “Functional expression of the rat glucagon-like peptide-I receptor, evidence for coupling to both adenylyl cyclase and phospholipase-C,” Endocrinology, vol. 133, no. 1, pp. 57–62, 1993. View at Publisher · View at Google Scholar · View at Scopus
  88. C. Montrose-Rafizadeh, P. Avdonin, M. J. Garant et al., “Pancreatic glucagon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in Chinese hamster ovary cells,” Endocrinology, vol. 140, no. 3, pp. 1132–1140, 1999. View at Google Scholar · View at Scopus
  89. C. A. Cullinan, E. J. Brady, R. Saperstein, and M. D. Leibowitz, “Glucose-dependent alterations of intracellular free calcium by glucagon-like peptide-1((7–36amide)) in individual ob/ob mouse beta-cells,” Cell Calcium, vol. 15, no. 5, pp. 391–400, 1994. View at Publisher · View at Google Scholar · View at Scopus
  90. C. Koole, D. Wootten, J. Simms et al., “Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening,” Molecular Pharmacology, vol. 78, no. 3, pp. 456–465, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. K. Coopman, Y. Huang, N. Johnston, S. J. Bradley, G. F. Wilkinson, and G. B. Willars, “Comparative effects of the endogenous agonist glucagon-like peptide-1 (GLP-1)-(7–36) amide and the small-molecule ago-allosteric agent "compound 2" at the GLP-1 receptor,” Journal of Pharmacology and Experimental Therapeutics, vol. 334, no. 3, pp. 795–808, 2010. View at Publisher · View at Google Scholar · View at Scopus
  92. A. Sassmann, B. Gier, H. J. Gröne, G. Drews, S. Offermanns, and N. Wettschureck, “The Gq/G11-mediated signaling pathway is critical for autocrine potentiation of insulin secretion in mice,” Journal of Clinical Investigation, vol. 120, no. 6, pp. 2184–2193, 2010. View at Publisher · View at Google Scholar · View at Scopus
  93. T. Yada, K. Itoh, and M. Nakata, “Glucagon-like peptide-1-(7–36)amide and a rise in cyclic adenosine 3,5- monophosphate increase cytosolic free Ca2+ in rat pancreatic beta-cells by enhancing Ca2+ activity,” Endocrinology, vol. 133, no. 4, pp. 1685–1692, 1993. View at Publisher · View at Google Scholar · View at Scopus
  94. T. Kenakin, “Efficacy in drug receptor theory: outdated concept or under-valued tool?” Trends in Pharmacological Sciences, vol. 20, no. 10, pp. 400–405, 1999. View at Publisher · View at Google Scholar · View at Scopus
  95. J. Guo, M. Liu, D. Yang et al., “Phospholipase C signaling via the parathyroid hormone (PTH)/PTH-related peptide receptor is essential for normal bone responses to PTH,” Endocrinology, vol. 151, no. 8, pp. 3502–3513, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. J. Takasaki, T. Saito, M. Taniguchi et al., “A novel Galphaq/11-selective inhibitor,” The Journal of Biological Chemistry, vol. 279, no. 46, pp. 47438–47445, 2004. View at Publisher · View at Google Scholar · View at Scopus
  97. R. Jorgensen, V. Kubale, M. Vrecl, T. W. Schwartz, and C. E. Elling, “Oxyntomodulin differentially affects glucagon-like peptide-1 receptor beta-arrestin recruitment and signaling through Galpha(s),” Journal of Pharmacology and Experimental Therapeutics, vol. 322, no. 1, pp. 148–154, 2007. View at Publisher · View at Google Scholar · View at Scopus
  98. N. J. Freedman and R. J. Lefkowitz, “Desensitization of G protein-coupled receptors,” Recent Progress in Hormone Research, vol. 51, pp. 319–351, 1996, discussion 352-353. View at Google Scholar · View at Scopus
  99. S. Rajagopal, K. Rajagopal, and R. J. Lefkowitz, “Teaching old receptors new tricks: biasing seven-transmembrane receptors,” Nature Reviews Drug Discovery, vol. 9, no. 5, pp. 373–386, 2010. View at Publisher · View at Google Scholar · View at Scopus
  100. J. Quoyer, C. Longuet, C. Broca et al., “GLP-1 mediates antiapoptotic effect by phosphorylating bad through a beta-arrestin 1-mediated ERK1/2 activation in pancreatic beta-cells,” The Journal of Biological Chemistry, vol. 285, no. 3, pp. 1989–2002, 2010. View at Publisher · View at Google Scholar · View at Scopus
  101. B. Luan, J. Zhao, H. Wu et al., “Deficiency of a beta-arrestin-2 signal complex contributes to insulin resistance,” Nature, vol. 457, no. 7233, pp. 1146–1149, 2009. View at Publisher · View at Google Scholar · View at Scopus
  102. Y. Li, T. Hansotia, B. Yusta, F. Ris, P. A. Halban, and D. J. Drueker, “Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis,” The Journal of Biological Chemistry, vol. 278, no. 1, pp. 471–478, 2003. View at Publisher · View at Google Scholar · View at Scopus
  103. Q. Wang and P. Brubaker, “Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice,” Diabetologia, vol. 45, no. 9, pp. 1263–1273, 2002. View at Publisher · View at Google Scholar · View at Scopus
  104. R. Burcelin and S. Dejager, “GLP-1: what is known, new and controversial in 2010?” Diabetes and Metabolism, vol. 36, no. 6, part 1, pp. 503–509, 2010. View at Publisher · View at Google Scholar · View at Scopus
  105. L. Farilla, A. Bulotta, B. Hirshberg et al., “Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets,” Endocrinology, vol. 144, no. 12, pp. 5149–5158, 2003. View at Publisher · View at Google Scholar · View at Scopus
  106. L. Tian, J. Gao, G. Weng et al., “Comparison of exendin-4 on beta-cell replication in mouse and human islet grafts,” Transplant International, vol. 24, no. 8, pp. 856–864, 2011. View at Publisher · View at Google Scholar
  107. M. E. Doyle and J. M. Egan, “Mechanisms of action of glucagon-like peptide 1 in the pancreas,” Pharmacology and Therapeutics, vol. 113, no. 3, pp. 546–593, 2007. View at Publisher · View at Google Scholar · View at Scopus
  108. D. Donnelly, “The structure and function of the glucagon-like peptide-1 receptor and its ligands,” British Journal of Pharmacology. In press.
  109. M. Dong, D. I. Pinon, Y. W. Asmann, and L. J. Miller, “Possible endogenous agonist mechanism for the activation of secretin family G protein-coupled receptors,” Molecular Pharmacology, vol. 70, no. 1, pp. 206–213, 2006. View at Publisher · View at Google Scholar · View at Scopus
  110. M. Dong, F. Gao, D. I. Pinon, and L. J. Miller, “Insights into the structural basis of endogenous agonist activation of family B G protein-coupled receptors,” Molecular Endocrinology, vol. 22, no. 6, pp. 1489–1499, 2008. View at Publisher · View at Google Scholar · View at Scopus
  111. M. Dong, D. I. Pinon, and L. J. Miller, “Site of action of a pentapeptide agonist at the glucagon-like peptide-1 receptor. Insight into a small molecule agonist-binding pocket,” Bioorganic and Medicinal Chemistry Letters, vol. 22, no. 1, pp. 638–641, 2012. View at Publisher · View at Google Scholar
  112. L. Covic, A. L. Gresser, J. Talavera, S. Swift, and A. Kuliopulos, “Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 2, pp. 643–648, 2002. View at Publisher · View at Google Scholar · View at Scopus
  113. J. M. Janz, Y. Ren, R. Looby et al., “Direct interaction between an allosteric agonist pepducin and the chemokine receptor CXCR4,” Journal of the American Chemical Society, vol. 133, no. 40, pp. 15878–15881, 2011. View at Publisher · View at Google Scholar
  114. S. Runge, S. Schimmer, J. Oschmann et al., “Differential structural properties of GLP-1 and exendin-4 determine their relative affinity for the GLP-1 receptor N-terminal extracellular domain,” Biochemistry, vol. 46, no. 19, pp. 5830–5840, 2007. View at Publisher · View at Google Scholar · View at Scopus
  115. R. L. de Maturana, A. Willshaw, A. Kuntzsch, R. Rudolph, and D. Donnelly, “The isolated N-terminal domain of the glucagon-like peptide-1 (GLP-1) receptor binds exendin peptides with much higher affinity than GLP-1,” The Journal of Biological Chemistry, vol. 278, no. 12, pp. 10195–10200, 2003. View at Publisher · View at Google Scholar · View at Scopus
  116. R. J. Mann, N. E. Nasr, J. K. Sinfield, E. Paci, and D. Donnelly, “The major determinant of exendin-4/glucagon-like peptide 1 differential affinity at the rat glucagon-like peptide 1 receptor N-terminal domain is a hydrogen bond from SER-32 of exendin-4: research paper,” British Journal of Pharmacology, vol. 160, no. 8, pp. 1973–1984, 2010. View at Publisher · View at Google Scholar · View at Scopus
  117. K. Schroder-Tittmann, E. Bosse-Doenecke, S. Reedtz-Runge et al., “Recombinant expression, in vitro refolding, and biophysical characterization of the human glucagon-like peptide-1 receptor,” Biochemistry, vol. 49, no. 36, pp. 7956–7965, 2010. View at Publisher · View at Google Scholar · View at Scopus
  118. A. Bisello, A. E. Adams, D. F. Mierke et al., “Parathyroid hormone-receptor interactions identified directly by photocross-linking and molecular modeling studies,” The Journal of Biological Chemistry, vol. 273, no. 35, pp. 22498–22505, 1998. View at Publisher · View at Google Scholar · View at Scopus
  119. M. Dong, Z. Li, D. I. Pinon, T. P. Lybrand, and L. J. Miller, “Spatial approximation between the amino terminus of a peptide agonist and the top of the sixth transmembrane segment of the secretin receptor,” The Journal of Biological Chemistry, vol. 279, no. 4, pp. 2894–2903, 2004. View at Publisher · View at Google Scholar · View at Scopus
  120. M. Dong, D. I. Pinon, R. F. Cox, and L. J. Miller, “Molecular approximation between a residue in the amino-terminal region of calcitonin and the third extracellular loop of the class B G protein-coupled calcitonin receptor,” The Journal of Biological Chemistry, vol. 279, no. 30, pp. 31177–31182, 2004. View at Publisher · View at Google Scholar · View at Scopus
  121. Z. Ji, E. M. Hadac, R. M. Henne, S. A. Patel, T. P. Lybrand, and L. J. Miller, “Direct identification of a distinct site of interaction between the carboxyl-terminal residue of cholecystokinin and the type A cholecystokinin receptor using photoaffinity labeling,” The Journal of Biological Chemistry, vol. 272, no. 39, pp. 24393–24401, 1997. View at Publisher · View at Google Scholar · View at Scopus
  122. Q. Chen, D. I. Pinon, L. J. Miller, and M. Dong, “Molecular basis of glucagon-like peptide 1 docking to its intact receptor studied with carboxyl-terminal photolabile probes,” The Journal of Biological Chemistry, vol. 284, no. 49, pp. 34135–34144, 2009. View at Publisher · View at Google Scholar · View at Scopus
  123. Q. Chen, D. I. Pinon, L. J. Miller, and M. Dong, “Spatial approximations between residues 6 and 12 in the amino-terminal region of glucagon-like peptide 1 and its receptor: a region critical for biological activity,” The Journal of Biological Chemistry, vol. 285, no. 32, pp. 24508–24518, 2010. View at Publisher · View at Google Scholar · View at Scopus
  124. L. J. Miller, Q. Chen, P. C.-H. Lam et al., “Refinement of glucagon-like peptide 1 docking to its intact receptor using mid-region photolabile probes and molecular modeling,” The Journal of Biological Chemistry, vol. 286, no. 18, pp. 15895–15907, 2011. View at Publisher · View at Google Scholar
  125. K. Adelhorst, B. B. Hedegaard, L. B. Knudsen, and O. Kirk, “Structure-activity studies of glucagon-like peptide-1,” The Journal of Biological Chemistry, vol. 269, no. 9, pp. 6275–6278, 1994. View at Google Scholar · View at Scopus
  126. S. W. Englander, T. R. Sosnick, J. J. Englander, and L. Mayne, “Mechanisms and uses of hydrogen exchange,” Current Opinion in Structural Biology, vol. 6, no. 1, pp. 18–23, 1996. View at Publisher · View at Google Scholar
  127. V. Katta and B. T. Chait, “Conformational changes in proteins probed by hydrogen-exchange electrospray-ionization mass spectrometry,” Rapid Communications in Mass Spectrometry, vol. 5, no. 4, pp. 214–217, 1991. View at Google Scholar
  128. X. Zhang, E. Y. T. Chien, M. J. Chalmers et al., “Dynamics of the beta2-adrenergic G-protein coupled receptor revealed by hydrogen-deuterium exchange,” Analytical Chemistry, vol. 82, no. 3, pp. 1100–1108, 2010. View at Publisher · View at Google Scholar · View at Scopus
  129. G. M. West, E. Y. T. Chien, V. Katritch et al., “Ligand-dependent perturbation of the conformational ensemble for the GPCR beta(2) adrenergic receptor revealed by HDX,” Structure, vol. 19, no. 10, pp. 1424–1432, 2011. View at Publisher · View at Google Scholar
  130. A. W. Kahsai, K. Xiao, S. Rajagopal et al., “Multiple ligand-specific conformations of the beta(2)-adrenergic receptor,” Nature Chemical Biology, vol. 7, no. 10, pp. 692–700, 2011. View at Publisher · View at Google Scholar
  131. K. Palczewski, T. Kumasaka, T. Hori et al., “Crystal structure of rhodopsin: a G protein-coupled receptor,” Science, vol. 289, no. 5480, pp. 739–745, 2000. View at Publisher · View at Google Scholar · View at Scopus
  132. J. A. Salon, D. T. Lodowski, and K. Palczewski, “The significance of G protein-coupled receptor crystallography for drug discovery,” Pharmacological Reviews, vol. 63, no. 4, pp. 901–937, 2011. View at Publisher · View at Google Scholar
  133. S. G. Rasmussen, B. T. Devree, Y. Zou et al., “Crystal structure of the beta(2) adrenergic receptor-Gs protein complex,” Nature, vol. 477, no. 7366, pp. 549–555, 2011. View at Publisher · View at Google Scholar
  134. P. S. Chae, S. G. F. Rasmussen, R. R. Rana et al., “Maltose-neopentyl glycol (MNG) amphiphiles for solubilization, stabilization and crystallization of membrane proteins,” Nature Methods, vol. 7, no. 12, pp. 1003–1008, 2010. View at Publisher · View at Google Scholar · View at Scopus
  135. D. M. Rosenbaum, V. Cherezov, M. A. Hanson et al., “GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function,” Science, vol. 318, no. 5854, pp. 1266–1273, 2007. View at Publisher · View at Google Scholar · View at Scopus
  136. S. G. Rasmussen, H.-J. Choi, J. J. Fung et al., “Structure of a nanobody-stabilized active state of the β2 adrenoceptor,” Nature, vol. 469, no. 7329, pp. 175–180, 2011. View at Publisher · View at Google Scholar
  137. M. Caffrey, “Crystallizing membrane proteins for structure-function studies using lipidic mesophases,” Biochemical Society Transactions, vol. 39, no. 3, pp. 725–732, 2011. View at Publisher · View at Google Scholar